>>> US Gapping Up

Gapping up
In reaction to strong earnings/guidance:

SCKT +24.6%, LOGI +13%, UIS +8.4%, VRTX +7.9%, (also, Vertex Pharma initiates two Phase 2 studies to evaluate the next-generation correctors VX-440 and VX-152 in triple combination regimens with tezacaftorand ivacaftor in people with cystic fibrosis), GRMN +7.1%, AKAM +6.7%, PNRA +5.5%, IRBT +4.9%,
JNPR +4.6%, NCR +3.5%, MRCY +3.1%, RRC +3.1%, OC +3%, BSX +2.5%, NOC +2.5%, CB +2.4%, NAP +2.1%, KO+1.8%, LEA +1.7%,
ESRX +1.6%, (also Express Scripts in 10-Q discloses recent receipt of civil investigative demand from the United States Attorney's Office & subpoena duces tecum from the DOJ and United States Attorney's Office)
BIIB +1.6%, MDR +1.5%, VNTV +1.4%, WM +1.4%, EXAS +1.3%, SAN +1.3%, EXC +1.3%, AOS +1.2%, BA +1.1%,CMCSA +0.7%, DGI +0.6%, CG +0.6%
M&A news: TWTR +3.1% (M&A blog Betaville discusses vague rumors that Disney (DIS) could again be looking at the company)

Other news:

OGXI +27% (announces positive survival results from the final analysis of the Phase 2 Borealis-2 trial)
LGCY +20.6% (executes a second lien term loan credit agreement with GSO Capital Partners LP to provide loans in an aggregate amount up to $300 million; adds additional director )
APRI +10.2% (announces that Greece has granted its commercialization partner, Recordati, market approval for Vitaros for erectile dysfunction)
FNBC +9.2% (First NBC Bank releases statement in response to 'unfounded assertions' and confirms it remains profitable)
DXPE +3.8% (downsizes and prices primary public offering of 2.16 mln shares of common stock at $19.70 per share)
CIEN +2.6% (JNPR sympathy)
DB +1.7% (report that DB is considering alternatives to bonus payment plans)
ARIA +1.5% (publication of preclinical data on brigatinib for the treatment of patients with anaplastic lymphoma kinase positive metastatic non-small cell lung cancer)
QGEN +1.2% (shareholders approve proposal to return approx. $250 mln in cash to shareholders through a synthetic share repurchase plan that combines a direct capital repayment with a reverse stock split)
CWEI +1% (following 25%+ move higher on Tuesday)

Analyst comments: